Clinical trial
Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe…
NCT00454051 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00454051 |
|---|---|
| Title | Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma |
| Official title | Double Blind Placebo Controlled Study to Assess the Expression of IgE on Basophils and Dendritic Cells During Omalizumab Treatment. |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Omalizumab, placebo |
| Enrollment | 31 |
| Start date | Dec 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Mar 29, 2007 |
| Last update posted | Aug 8, 2011 |
| Countries | France |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: